# | Title | Journal | Year | Citations |
---|
1 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 6,961 |
2 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | New England Journal of Medicine | 2012 | 6,820 |
3 | The Cancer Genome Atlas Pan-Cancer analysis project | Nature Genetics | 2013 | 6,265 |
4 | Inferring tumour purity and stromal and immune cell admixture from expression data | Nature Communications | 2013 | 5,788 |
5 | NF-κB signaling in inflammation | Signal Transduction and Targeted Therapy | 2017 | 4,812 |
6 | The biology , function , and biomedical applications of exosomes | Science | 2020 | 4,742 |
7 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
8 | Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? | Nature Reviews Drug Discovery | 2009 | 4,327 |
9 | Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer | New England Journal of Medicine | 2004 | 4,124 |
10 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 | Cell Death and Differentiation | 2018 | 4,036 |
11 | Definition and classification of cancer cachexia: an international consensus | Lancet Oncology, The | 2011 | 4,015 |
12 | Oxidative stress, inflammation, and cancer: How are they linked? | Free Radical Biology and Medicine | 2010 | 3,991 |
13 | The Somatic Genomic Landscape of Glioblastoma | Cell | 2013 | 3,979 |
14 | The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging | Ca-A Cancer Journal for Clinicians | 2017 | 3,940 |
15 | One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States | Journal of Clinical Oncology | 2008 | 3,875 |
16 | A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 | Nature Immunology | 2005 | 3,869 |
17 | The Immune Landscape of Cancer | Immunity | 2018 | 3,706 |
18 | 1994 Consensus Conference on Acute GVHD Grading | Bone Marrow Transplantation | 1995 | 3,571 |
19 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Cell | 2017 | 3,483 |
20 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | New England Journal of Medicine | 2018 | 3,334 |
21 | The 2015 World Health Organization Classification of Lung Tumors | Journal of Thoracic Oncology | 2015 | 3,313 |
22 | Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | New England Journal of Medicine | 2003 | 3,227 |
23 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia | New England Journal of Medicine | 2006 | 3,212 |
24 | Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients | Science | 2018 | 3,126 |
25 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
26 | The biology and function of fibroblasts in cancer | Nature Reviews Cancer | 2016 | 2,886 |
27 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance | Hepatology | 2018 | 2,620 |
28 | Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Nature Genetics | 1997 | 2,596 |
29 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | New England Journal of Medicine | 2019 | 2,594 |
30 | Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome | New England Journal of Medicine | 2001 | 2,593 |
31 | IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade | Journal of Clinical Investigation | 2017 | 2,560 |
32 | Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer | New England Journal of Medicine | 1991 | 2,537 |
33 | Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis | JAMA - Journal of the American Medical Association | 2011 | 2,529 |
34 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | New England Journal of Medicine | 2012 | 2,474 |
35 | Revised International Prognostic Scoring System for Myelodysplastic Syndromes | Blood | 2012 | 2,458 |
36 | Tumour evolution inferred by single-cell sequencing | Nature | 2011 | 2,313 |
37 | Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States | JAMA Oncology | 2017 | 2,289 |
38 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics | Cell | 2018 | 2,277 |
39 | A Landscape of Driver Mutations in Melanoma | Cell | 2012 | 2,247 |
40 | Guidelines for the Prevention of Intravascular Catheter-related Infections | Clinical Infectious Diseases | 2011 | 2,242 |
41 | Glypican-1 identifies cancer exosomes and detects early pancreatic cancer | Nature | 2015 | 2,240 |
42 | How We Design Feasibility Studies | American Journal of Preventive Medicine | 2009 | 2,233 |
43 | Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors | New England Journal of Medicine | 2017 | 2,206 |
44 | SPIKES—A Six‐Step Protocol for Delivering Bad News: Application to the Patient with Cancer | Oncologist | 2000 | 2,157 |
45 | Next-generation characterization of the Cancer Cell Line Encyclopedia | Nature | 2019 | 2,149 |
46 | Whole genomes redefine the mutational landscape of pancreatic cancer | Nature | 2015 | 2,132 |
47 | Fundamental Mechanisms of Immune Checkpoint Blockade Therapy | Cancer Discovery | 2018 | 2,128 |
48 | Oncogenic Signaling Pathways in The Cancer Genome Atlas | Cell | 2018 | 2,111 |
49 | Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma | Cancer Cell | 2010 | 2,078 |
50 | A note on quantifying follow-up in studies of failure time | Contemporary Clinical Trials | 1996 | 2,072 |